Tax-related share sale by Corbus (CRBP) COO after RSU vesting

Rhea-AI Filing Summary

Corbus Pharmaceuticals Holdings, Inc.’s Chief Operating Officer Ian Hodgson reported an open-market sale of 847 shares of common stock at a weighted-average price of $7.383 per share. According to the disclosure, this sale was mandated as a “sell to cover” transaction to satisfy tax withholding obligations tied to the vesting and settlement of restricted stock units and was not a discretionary trade.

After the transaction, Hodgson directly held 51,080 shares, which the disclosure notes includes 46,362 unvested restricted stock units that continue to vest under their existing schedules.

Insider Trade Summary

Net Seller: 847 shares ($6,253)

Net Sell 1 txn

Insider Hodgson Ian

Role Chief Operating Officer

Sold 847 shs ($6K)

Type	Security	Shares	Price	Value
Sale	Common Stock, par value $0.0001 per share	847	$7.383	$6K

Holdings After Transaction: Common Stock, par value $0.0001 per share — 51,080 shares (Direct)

Footnotes (1)

1. The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of Restricted Stock Units ("RSUs"). The sale is mandated by the Issuer's election to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person. The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $7.37 to $7.42. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. This amount includes 46,362 unvested RSUs subject to each grant's vesting schedule as previously reported.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Hodgson Ian

(Last) (First) (Middle)

C/O CORBUS PHARMACEUTICALS HOLDINGS, INC

500 RIVER RIDGE DRIVE

(Street)

NORWOOD MA 02062

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Corbus Pharmaceuticals Holdings, Inc. [ CRBP ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Operating Officer

3. Date of Earliest Transaction (Month/Day/Year)
02/17/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock, par value $0.0001 per share	02/17/2026		S(1)		847	D	$7.383(2)	51,080(3)	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of Restricted Stock Units ("RSUs"). The sale is mandated by the Issuer's election to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person.

2. The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $7.37 to $7.42. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

3. This amount includes 46,362 unvested RSUs subject to each grant's vesting schedule as previously reported.

	/s/ Meghan Houghton, attorney-in-fact for Ian Hodgson	02/18/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did Corbus Pharmaceuticals (CRBP) report for Ian Hodgson?

Ian Hodgson reported selling 847 shares of Corbus Pharmaceuticals common stock. The sale was an open-market transaction executed to cover tax withholding obligations related to vesting restricted stock units, rather than a discretionary decision to reduce his investment position.

Why did the Corbus Pharmaceuticals (CRBP) COO sell 847 shares?

The 847 shares were sold to cover tax withholding obligations from the vesting and settlement of restricted stock units. The company required a “sell to cover” transaction, meaning the sale was mandated for tax purposes and not initiated as a voluntary portfolio change.

What price did the Corbus Pharmaceuticals (CRBP) COO receive for the sold shares?

The reported weighted-average sale price was $7.383 per share. The filing notes that multiple trades occurred within a range from $7.37 to $7.42, and detailed breakdowns of each individual trade price are available upon request from the company or regulators.

How many Corbus Pharmaceuticals (CRBP) shares does Ian Hodgson hold after the sale?

Following the tax-related sale, Ian Hodgson directly holds 51,080 shares of Corbus common stock. This figure includes 46,362 unvested restricted stock units that remain subject to their previously disclosed vesting schedules and have not been sold in this transaction.

Was the Corbus Pharmaceuticals (CRBP) COO’s share sale discretionary?

No, the sale was not discretionary. The company elected to satisfy tax withholding obligations via a mandatory “sell to cover” transaction, so the shares were automatically sold to pay taxes due upon restricted stock unit vesting rather than through an elective trading decision.

What does the weighted-average price range mean in this Corbus (CRBP) Form 4?

The filing reports a weighted-average sale price of $7.383, with individual trades between $7.37 and $7.42. This means multiple executions occurred within that range, and the insider offers to provide a full price-by-trade breakdown to shareholders or regulators if requested.